A retrospective single-center cohort study assessing the impact of gastrointestinal (GI) involvement on clinical outcomes of patients treated with standard of care CD19-targeted CAR T cell therapy
Latest Information Update: 26 Oct 2021
Price :
$35 *
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2021 New trial record
- 01 Sep 2021 Results published in the Transplantation and Cellular Therapy